Partial Exercise of Over-Allotment Option
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION
Verona Pharma Announces Partial Exercise of Over-allotment Option
and Resulting Total Voting Rights
All of the ADSs in the Global Offering were sold by Verona Pharma and are trading on the
Jefferies and Stifel acted as joint book-running managers for the Global Offering. Wedbush PacGrow and SunTrust Robinson Humphrey acted as co-managers.
Application has been made for the 5,539,080 new ordinary shares issued by Verona Pharma pursuant to the partial exercise of the over-allotment option, represented by the 692,385 ADSs, to be admitted to trading on AIM and it is expected that admission will become effective and dealings in the new ordinary shares will commence at
Following the closing of the partial exercise of the over-allotment option, the issued share capital of Verona Pharma will be 104,553,244 ordinary shares and this figure may be used by shareholders as a denominator for the calculations by which they will determine if they are required to notify their interest in, or change to their interest in, Verona Pharma, under the Disclosure Guidance and Transparency Rules published by the
A registration statement relating to these securities was declared effective by the
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.
For readers in the European Economic Area
In any EEA Member State that has implemented the Prospectus Directive (as defined below), this communication is only addressed to and directed at qualified investors in that Member State within the meaning of the Prospectus Directive. The term "Prospectus Directive" means Directive 2003/71/EC (and amendments thereto, including Directive 2010/73/EU, to the extent implemented in each relevant Member State), together with any relevant implementing measure in the relevant Member State.
For readers in the
There will be no offer of ADSs or ordinary shares to the public in the
This communication, in so far as it constitutes an invitation or inducement to enter into investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000 as amended ("FSMA")) in connection with the securities which are the subject of the offering described in this press release or otherwise, is being directed only at (i) persons who are outside the
For further information, please contact:
Verona Pharma plc |
Tel: +44 (0)20 3283 4200 |
Jan-Anders Karlsson, Chief Executive Officer |
|
|
|
N+1 Singer (Nominated Adviser and UK Broker) |
Tel: +44 (0)20 7496 3000 |
Aubrey Powell / James White |
|
|
|
FTI Consulting (UK Media and Investor enquiries) |
Tel: +44 (0)20 3727 1000 |
Simon Conway / Stephanie Cuthbert / Natalie Garland-Collins |
|
|
|
ICR, Inc. (US Media and Investor enquiries) |
|
James Heins |
Tel: +1 203-682-8251 |
Stephanie Carrington |
Tel. +1 646-277-1282 |
This information is provided by RNS